Ma Qingyong, Wang Yunjian, Gao Xiaopeng, Ma Zhenhua, Song Zhengjun
Departments of General Surgery, The First Hospital of Xi'an Jiaotong University, Xi'an, PR China.
Clin Cancer Res. 2007 Dec 15;13(24):7407-12. doi: 10.1158/1078-0432.CCR-07-0751.
Evidence suggests that the majority of colorectal carcinomas arise from adenomas, and L-arginine suppresses colorectal tumorigenesis. We suppose that L-arginine may inhibit the process of carcinogenesis from colorectal adenoma to adenocarcinoma. The aim of this study was to investigate the effects of L-arginine on the formation and development of colorectal tumors.
We selected 60 patients with colorectal cancer and 60 patients with colorectal adenoma (CRA) and divided them into four groups of 30 patients each. We gave 30 g (120 mL) of L-arginine everyday for 3 days to the test groups, whereas L-arginine was substituted by 5% glucose in the control groups. The expression of the proliferating cell nuclear antigen, survivin, and nitric oxide synthase was examined immunohistochemically, and ornithine decarboxylase (ODC) activity was examined spectrophotometrically. Serum nitric oxide (NO) was detected by the Griess assay.
In patients with CRA, the proliferating cell nuclear antigen and survivin labeling indexes and ODC activity of the tumor and paratumor mucosa in the L-arginine-treated group after L-arginine treatment were significantly lower as compared with the corresponding pretreatment values (P < 0.01). Moreover, inducible nitric oxide synthase expression in the tumor markedly increased after L-arginine treatment (P < 0.05). Serum NO levels in the patients with colorectal cancer were markedly higher than those in the patients with CRA, and L-arginine treatment was responsible for this increase (P < 0.05).
Our results show that L-arginine can restrain crypt cell hyperproliferation and the expression of survivin, an inhibitor of apoptosis protein. This suggests that L-arginine can block the formation and development of colorectal tumors, and this effect might be related to the increased serum NO concentration and decreased ODC activity.
有证据表明,大多数结直肠癌起源于腺瘤,且L-精氨酸可抑制结直肠癌发生。我们推测L-精氨酸可能抑制从结直肠腺瘤到腺癌的癌变过程。本研究旨在探讨L-精氨酸对结直肠肿瘤形成和发展的影响。
我们选取了60例结直肠癌患者和60例结直肠腺瘤(CRA)患者,将他们分为四组,每组30例。给试验组患者连续3天每天服用30 g(120 mL)L-精氨酸,而对照组用5%葡萄糖替代L-精氨酸。采用免疫组织化学法检测增殖细胞核抗原、生存素和一氧化氮合酶的表达,用分光光度法检测鸟氨酸脱羧酶(ODC)活性。采用格里斯试剂法检测血清一氧化氮(NO)。
在CRA患者中,L-精氨酸治疗组治疗后肿瘤及瘤旁黏膜的增殖细胞核抗原和生存素标记指数以及ODC活性均显著低于相应的治疗前值(P < 0.01)。此外,L-精氨酸治疗后肿瘤中诱导型一氧化氮合酶表达明显增加(P < 0.05)。结直肠癌患者的血清NO水平明显高于CRA患者,L-精氨酸治疗导致了这种升高(P < 0.05)。
我们的结果表明,L-精氨酸可抑制隐窝细胞过度增殖以及凋亡抑制蛋白生存素的表达。这表明L-精氨酸可阻断结直肠肿瘤的形成和发展,且这种作用可能与血清NO浓度升高和ODC活性降低有关。